KIF2Ci

Model: ＮＡ

Booth No: N915

Characteristic

Here we present the first-in-class small-molecule inhibitor targeting KIF2C, which is overexpressed in 75% of solid tumors and linked to proliferation, metastasis, immune evasion, and chemoresistance. KIF2C inhibitor (KIF2Ci) shows synergy with over 50% of clinical chemotherapeutics, enhancing efficacy and delaying resistance. Published in Developmental Cell, KIF2Ci demonstrates high specificity for recurrent, metastatic triple-negative breast cancer, offering a breakthrough treatment. It holds strong potential for combination therapy across various solid and drug-resistant cancers with significant commercial value.